EuroPCR 2024 | Complete revascularization affects clinical outcomes? REVIVED.BCIS2 Insights

Complete revascularization has shown in several studies and meta-analysis a benefit in mortality vs. incomplete revascularization.

The REVIVED-BCIS looked at whether there were differences in mortality and hospitalization for cardiac failure in patients with ventricular function deterioration and viability when comparing coronary angioplasty(PCI) against optimal medical treatment. This study showed that PCI was not associated with significant changes in the established final outcomes. 

Of 266 patients undergoing PCI, 130 received complete revascularization and 136 incomplete revascularization. Complete revascularization was defined as anatomical according to coronary revascularization index (Δ Score BCIS), or viability guided, according to myocardial revascularization index.

In terms of anatomical revascularization, there were no significant differences between incomplete anatomical revascularization and optimal medical treatment (HR 0.97; P=0.85). Also, complete anatomical revascularization did not show significant differences (HR 0.90; P=0.59).

Read also: EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis.

When looking at viability guided revascularization, neither were there differences in favor of revascularization vs optimal medical treatment, both with complete (HR 0.95; p=0.76) and incomplete revascularization (HR 0.83; p=0.28).

Authors’ conclusion: The REVIVED-BCIS2, on patients with stable coronary artery disease and severe ventricular dysfunction, neither complete anatomical revascularization or viability guided revascularization generated changes in clinical events. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Margaret Mcentegart, at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...